Objective： To investigate the effect of Chinese medicine （CM） on survival of patients with stage Ⅱ and Ⅲ colorectal cancer （CRC）. Methods： A total of 295 patients who received chemotherapy were assigned to Gro...Objective： To investigate the effect of Chinese medicine （CM） on survival of patients with stage Ⅱ and Ⅲ colorectal cancer （CRC）. Methods： A total of 295 patients who received chemotherapy were assigned to Group 1. The other 171 patients received the same chemotherapy treatment combined with the usage of CM Jianpi Jiedu Formula （健脾解毒方, JPJD） for more than 3 months （Group 2）. Patients＇ survival time, relapse and metastasis, and cause of death were observed. Cox proportional hazard regression models were established for the analysis of the effect of independent factors on the survival prognosis of patients with CRC. Results： The survival rate of patients in Group 2 was higher than that of Group 1 （P〈0.05）. Compared with Group 1, the mean survival time was prolonged by 5.594 months and the median survival time was prolonged by 6 months in Group 2 （P=0.004）. Cox regression analysis indicated that CM combined with chemotherapy provided significant protective effect, as observed with the improvements in the survival rates of CRC patients （P〈0.01）. Conclusion： CM can improve the survival rate in patients with stage Ⅱ and Ⅲ CRC.展开更多
基金Supported by the National Natural Science Foundation of China(No.81273722)
文摘Objective： To investigate the effect of Chinese medicine （CM） on survival of patients with stage Ⅱ and Ⅲ colorectal cancer （CRC）. Methods： A total of 295 patients who received chemotherapy were assigned to Group 1. The other 171 patients received the same chemotherapy treatment combined with the usage of CM Jianpi Jiedu Formula （健脾解毒方, JPJD） for more than 3 months （Group 2）. Patients＇ survival time, relapse and metastasis, and cause of death were observed. Cox proportional hazard regression models were established for the analysis of the effect of independent factors on the survival prognosis of patients with CRC. Results： The survival rate of patients in Group 2 was higher than that of Group 1 （P〈0.05）. Compared with Group 1, the mean survival time was prolonged by 5.594 months and the median survival time was prolonged by 6 months in Group 2 （P=0.004）. Cox regression analysis indicated that CM combined with chemotherapy provided significant protective effect, as observed with the improvements in the survival rates of CRC patients （P〈0.01）. Conclusion： CM can improve the survival rate in patients with stage Ⅱ and Ⅲ CRC.
